Nonclinical development of biopharmaceuticals

Drug Discovery Today

Volumn 14, Issue 23-24, 2009, Pages 1112-1122

  Baumann, Andreas ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL PRODUCT; INSULIN; INTERFERON; TGN 1412;

ANTIBODY PRODUCTION; BINDING AFFINITY; BIOTECHNOLOGY; CARCINOGENICITY; CLINICAL TRIAL; DISEASE MODEL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSPORT; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MOLECULAR WEIGHT; NONHUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PRODUCT DEVELOPMENT; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXICITY TESTING;

ANIMALS; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; DRUG EVALUATION, PRECLINICAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL; TOXICITY TESTS;

EID: 71749108118     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.09.013     Document Type: Review

References (69)

1. Baumann A. Preclinical development of therapeutic biologics. Expert Opin. Drug Discov. 3 (2008) 289-297
2. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol. 23 (2005) 553-558
3. Pavlou A.K., and Reichert J.M. Recombinant protein therapeutics - success rates, market trends and values 2010. Nat. Biotechnol. 22 (2004) 1513-1519
4. Reichert J.M., and Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6 (2007) 349-356
5. Gerber D.E., and Laterra J. Emerging monoclonal antibody therapies for malignant gliomas. Expert Opin. Investig. Drugs 16 (2007) 477-494
6. Reichert J.M., et al. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23 (2005) 1073-1078
7. Cavagnaro J.A., and Dayan A.B. Foreword. In: Cavagnaro J.A. (Ed). Preclinical Safety Evaluation of Biopharmaceuticals (2008), Wiley & Sons
8. Baumann A. Early development of therapeutic biologics - pharmacokinetics. Curr. Drug Metab. 7 (2006) 15-21
9. ICH S 6. Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals (1997) (CPMP/ICH/302/595)
10. Snodin D.J., and Ryle P.R. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. BioDrugs 20 (2006) 25-52
11. In: Maibohm B. (Ed). Pharmacokinetics and Pharmacodynamic of Biotech Drugs (2006), Wiley-VCH
12. EMEA, and CHMP. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (2007) (EMEA/CHMP/BMWP/14327/2006)
13. FDA planned guidances for assay development for immunogenicity testing and immunogenicity assessment for therapeutic protein products (http://www.fda.gov/cder/guidance/CY09.pdf)
14. EMEA, and CHMP. Concept Paper on Immunogenicity Assessment for Monoclonal Antibodies Intended for In Vivo Clinical Use (2009) (EMEA/CHMP/BMWP/114720/2009)
15. EMEA, and CHMP. Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins (2007) (EMEA/CHMP/EWP/89249/2004)
16. EMEA, and CHMP. Guideline on Comparability of Biotechnology-derived Medicinal Products after Change in the Manufacturing Process, Non-clinical and Clinical Issues (2007) (EMEA/CHMP/BWMP/101695/2006)
17. EMEA, and CHMP. Guideline on Strategies to Identify and Mitigate Risks for First in Human Clinical Trials with Investigational Medicinal Products (2007) (EMEA/CHMP/SWP/294648/2007)
18. Buckley L.A., et al. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop. Int. J. Toxicol. 27 (2008) 303-312
19. Dempster A.M. Nonclinical safety evaluation of biotechnology derived pharmaceuticals. Biotechnol. Annu. Rev. 5 (2000) 221-258
20. Suntharalingam G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 (2006) 1018-1028
21. Giezen T.J., et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300 (2008) 1887-1896
22. Tabrizi M.A., and Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12 (2007) 540-547
23. Clarke J., et al. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?. Regul. Toxicol. Pharmacol. 50 (2008) 2-22
24. Bussiere J.L. General toxicity testing and immunotoxicity testing for biopharmaceuticals. In: Cavagnaro J.A. (Ed). Preclinical Safety Evaluation of Biopharmaceuticals (2008), Wiley & Sons 343-356
25. Ponce R., et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54 (2009) 164-182
26. Bolon B. Genetically engineered animals in drug discovery and development: a maturing resource for toxicologic research. Basic Clin. Pharmacol. Toxicol. 95 (2004) 154-161
27. Koppele J.T., and Witkamp R. Use of animal models of disease in the preclinical safety evaluation of biopharmaceuticals. In: Cavagnaro J.A. (Ed). Preclinical Safety Evaluation of Biopharmaceuticals (2008), Wiley & Sons 293-308
28. Bugelski P.J., et al. Preclinical development of keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum. Exp. Toxicol. 19 (2000) 230-243
29. Ich M3. Note for Guidance on Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (2000) (CPMP/ICH/286/95)
30. Fda CBER. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (1997)
31. Fda CBER. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (2005)
32. Horvath C. Comparison of preclinical development programs for small molecules and large molecules: studies, timing, materials; and costs. In: Cavagnaro J.A. (Ed). Preclinical Safety Evaluation of Biopharmaceuticals (2008), Wiley & Sons 125-159
33. ICH S 7 A. Safety Pharmacology Studies for Human Pharmaceuticals (2001) (CPMP/ICH/539/00)
34. ICH S 7 A. The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (2005) (CPMP/ICH/432/02)
35. Tang L., et al. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93 (2004) 2184-2204
36. Tang L., and Meibohm B. Pharmacokinetics of peptides and proteins. In: Maibohm B. (Ed). Pharmacokinetics and Pharmacodynamics of Biotech Drugs (2006), Wiley-VCH 17-43
37. Schellekens H., and Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 251 (2004) II/4-II/9
38. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatrid arthritis. N. Engl. J. Med. 355 (2006) 704-712
39. Parnham M.J., et al. Non-clinical safety studies on biosimilar recombinant human erythropoietin. Basic Clin. Pharmacol. Toxicol. 100 (2007) 73-83
40. Shankar G., et al. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24 (2006) 274-280
41. Weirda A.D., et al. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 98 (2001) 2599-2602
42. Bugelski P.J., and Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6 (2004) 10-16
43. De Groot A.S., et al. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr. Opin. Pharmacol. 8 (2008) 620-626
44. De Groot A.S., and Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol. 28 (2007) 482-490
45. Van Walle I., et al. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 7 (2007) 405-418
46. Van der Walle C.F., et al. Current approaches to stabilising and analysing proteins during microencapsulation in PLGA. Expert Opin. Drug Deliv. 6 (2009) 177-186
47. Lobo E.D., et al. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93 (2004) 2645-2668
48. Toon S. The relevance of pharmacokinetics in the development of biotechnology drugs. Eur. J. Drug 21 (1996) 93-103
49. Carter P.J., and Senter P.D. Antibody-drug conjugates for cancer therapy. Cancer J. 74 (2008) 154-169
50. Webster R., et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. 35 (2007) 9-16
51. Mahmood I., and Green M.D. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J. Clin. Pharmacol. 47 (2007) 1540-1554
52. Seitz K., and Zhou H. Pharmacokinetic drug drug interaction potentials for therapeutic monoclonal antibodies: reality check. J. Clin. Pharmacol. 47 (2007) 1104-1118
53. Zhou H., and Davis H.M. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov. Today 14 (2009) 891-898
54. Tabrizi M.A., et al. Elimination mechanism of therapeutic monoclonal antibodies. Drug Discov. Today 11 (2006) 81-88
55. Mould D.R., et al. Population pharmacokinetics-pharmacodynamics of alemtuzuMAb in patients with chronic lymphcytic leukaemia and its link to treatment response. Br. J. Clin. Pharmacol. 64 (2007) 278-291
56. Mahmood I. Pharmacodynamics. In: Mahmood I. (Ed). Clinical Pharmacology of Therapeutic Proteins (2006), Pine House Publishers 63-93
57. Dong J.Q., et al. Predicting human pharmacokinetics of mAbs with linear and non-linear elimination based only on monkey data; Poster presentation. NBC-AAPS Meeting. Seattle, June (2009) 21-24
58. Summerfield S., and Jeffrey P. Discovery DMPK: changing paradigms in the eighties, nineties and noughties. Expert Opin. Drug Discov. 4 (2009) 207-218
59. Yeung Y.A., et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J. Immunol. (2009) 7663-7671
60. Qin C.J., et al. Mass spectrometric approaches for protein quantitation in drug development. Am. Pharm. Rev. 7 (2004) 4-89
61. DeSilva B., et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20 (2003) 1885-1900
62. Wadhwa M., et al. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278 (2003) 1-17
63. Mire-Sluis A.R., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289 (2004) 1-16
64. Gupta S., et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321 (2007) 1-18
65. Indelicato S.R. Assays for the detection of antibodies - current scientific challenges. In: Brown F., and Mire-Sluis A.R. (Eds). Immunogenicity of Therapeutic Biological Products (2003), Karger 105-139
66. Koren E., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333 (2008) 1-9
67. Shankar G., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48 (2008) 1267-1281
68. Shankar G., et al. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25 (2007) 555-561
69. Rosenberg A.S., and Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1: considering consequences of the immune response to a protein. Biopharm. Int. 17 (2004) 34-42